Mr. David Burke reports

CHAIR OF SERNOVA BIOTHERAPEUTICS RESIGNS

Sernova Biotherapeutics Inc.'s chair has resigned.

Ross Haghighat tendered his resignation on May 24, and his resignation was accepted by the Sernova board. The board of directors of Sernova thanks Mr. Haghighat for his service as a trusted leader and sincerely wishes him luck in the future.

About Sernova Biotherapeutics Inc.

Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its cell pouch with human donor cells or stem-cell-derived islet-like clusters in collaboration with Evotec to create biohybrid organs to treat T1D. A biohybrid organ is composed of non-biomaterials, such as the cell pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on T1D and thyroid disorders.